The effect of long-term administration of lorglumide (cr 1409) on rat pancreatic growth and enzyme composition

T. Takács, István Nagy, A. Pap, Vince Varró

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The effects of lorglumide (CR 1409), a potent cholecystokinin (CCK) receptor blocker developed recently by the Rotta Research Laboratories, were studied on pancreatic growth and enzyme composition. In secretory studies, the inhibitory effect of 4 mg/kg of lorglumide administered subcutaneously proved to last more than 3 h. The trophic effect of exogenous CCK (600 ng/kg given three times daily for 2 weeks) was significantly decreased by the simultaneous administration of 4 mg/kg of lorglumide. To study the role of endogenous CCK released by feeding while maintaining pancreatic trophism, 4 mg/kg of lorglumide was administered subcutaneously four times daily during the feeding period for 2 weeks. Lorglumide significantly decreased pancreatic weight, pancreatic content of soluble protein, trypsinogen, and chymo-trypsinogen, while decreases in DNA, lipase, and amylase failed to reach statistical significance. According to our experiments, high-doses of lorglumide could inhibit not only the trophic effect of exogenous CCK but also the effect of endogenous CCK released by food and lorglumide itself.

Original languageEnglish
Pages (from-to)606-610
Number of pages5
JournalPancreas.
Volume5
Issue number5
Publication statusPublished - 1990

Fingerprint

Cholecystokinin
Enzymes
Growth
Trypsinogen
Cholecystokinin Receptors
lorglumide
Amylases
Lipase
Weights and Measures
Food
DNA
Research
Proteins

Keywords

  • Antitrophic effect
  • Exogenous and endogenous CCK
  • Lor-glumide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Internal Medicine
  • Gastroenterology

Cite this

The effect of long-term administration of lorglumide (cr 1409) on rat pancreatic growth and enzyme composition. / Takács, T.; Nagy, István; Pap, A.; Varró, Vince.

In: Pancreas., Vol. 5, No. 5, 1990, p. 606-610.

Research output: Contribution to journalArticle

@article{c53f05799cd44a64b5f5f02029ec9349,
title = "The effect of long-term administration of lorglumide (cr 1409) on rat pancreatic growth and enzyme composition",
abstract = "The effects of lorglumide (CR 1409), a potent cholecystokinin (CCK) receptor blocker developed recently by the Rotta Research Laboratories, were studied on pancreatic growth and enzyme composition. In secretory studies, the inhibitory effect of 4 mg/kg of lorglumide administered subcutaneously proved to last more than 3 h. The trophic effect of exogenous CCK (600 ng/kg given three times daily for 2 weeks) was significantly decreased by the simultaneous administration of 4 mg/kg of lorglumide. To study the role of endogenous CCK released by feeding while maintaining pancreatic trophism, 4 mg/kg of lorglumide was administered subcutaneously four times daily during the feeding period for 2 weeks. Lorglumide significantly decreased pancreatic weight, pancreatic content of soluble protein, trypsinogen, and chymo-trypsinogen, while decreases in DNA, lipase, and amylase failed to reach statistical significance. According to our experiments, high-doses of lorglumide could inhibit not only the trophic effect of exogenous CCK but also the effect of endogenous CCK released by food and lorglumide itself.",
keywords = "Antitrophic effect, Exogenous and endogenous CCK, Lor-glumide",
author = "T. Tak{\'a}cs and Istv{\'a}n Nagy and A. Pap and Vince Varr{\'o}",
year = "1990",
language = "English",
volume = "5",
pages = "606--610",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The effect of long-term administration of lorglumide (cr 1409) on rat pancreatic growth and enzyme composition

AU - Takács, T.

AU - Nagy, István

AU - Pap, A.

AU - Varró, Vince

PY - 1990

Y1 - 1990

N2 - The effects of lorglumide (CR 1409), a potent cholecystokinin (CCK) receptor blocker developed recently by the Rotta Research Laboratories, were studied on pancreatic growth and enzyme composition. In secretory studies, the inhibitory effect of 4 mg/kg of lorglumide administered subcutaneously proved to last more than 3 h. The trophic effect of exogenous CCK (600 ng/kg given three times daily for 2 weeks) was significantly decreased by the simultaneous administration of 4 mg/kg of lorglumide. To study the role of endogenous CCK released by feeding while maintaining pancreatic trophism, 4 mg/kg of lorglumide was administered subcutaneously four times daily during the feeding period for 2 weeks. Lorglumide significantly decreased pancreatic weight, pancreatic content of soluble protein, trypsinogen, and chymo-trypsinogen, while decreases in DNA, lipase, and amylase failed to reach statistical significance. According to our experiments, high-doses of lorglumide could inhibit not only the trophic effect of exogenous CCK but also the effect of endogenous CCK released by food and lorglumide itself.

AB - The effects of lorglumide (CR 1409), a potent cholecystokinin (CCK) receptor blocker developed recently by the Rotta Research Laboratories, were studied on pancreatic growth and enzyme composition. In secretory studies, the inhibitory effect of 4 mg/kg of lorglumide administered subcutaneously proved to last more than 3 h. The trophic effect of exogenous CCK (600 ng/kg given three times daily for 2 weeks) was significantly decreased by the simultaneous administration of 4 mg/kg of lorglumide. To study the role of endogenous CCK released by feeding while maintaining pancreatic trophism, 4 mg/kg of lorglumide was administered subcutaneously four times daily during the feeding period for 2 weeks. Lorglumide significantly decreased pancreatic weight, pancreatic content of soluble protein, trypsinogen, and chymo-trypsinogen, while decreases in DNA, lipase, and amylase failed to reach statistical significance. According to our experiments, high-doses of lorglumide could inhibit not only the trophic effect of exogenous CCK but also the effect of endogenous CCK released by food and lorglumide itself.

KW - Antitrophic effect

KW - Exogenous and endogenous CCK

KW - Lor-glumide

UR - http://www.scopus.com/inward/record.url?scp=0025102341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025102341&partnerID=8YFLogxK

M3 - Article

C2 - 1700417

AN - SCOPUS:0025102341

VL - 5

SP - 606

EP - 610

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -